Alexander Green says there are two key elements to a perfect stock.
First, it has to be undiscovered and it should also trade for just a few dollars a share. It may seem improbable that such a stock exists, but it does, and Alex calls it his “#1 AI Stock.”
The Teaser
The company behind the stock may be involved in the most important new technology – EVER and it could become the cornerstone of our retirement.
Alexander Green is a 20-year Wall Street vet and the Chief Investment Strategist of The Oxford Club, which has a murky past, as we went over in our Is The Oxford Club A Fraud. We have also made it a habit of regularly reviewing Alex's picks, like his “Next Great American Super Stock.”
So what is this revolutionary new technology?
Alex is of course talking about the explosion in artificial intelligence (AI) over the past year and a quarter.
According to Stanford Professor Steve Blank, “AI is going to reinvent every possible piece of commerce and enterprise in the next year.”
This is good news for us because Alex says the company he's going to tell us about today “will become the most important AI company in the world over the coming years.”
The reason he is so confident is because it's almost an identical situation to one of the best calls of his career, Intuitive Surgical (Nasdaq: ISRG).
Back in 2004, when Intuitive was trading for less than $24 per share, Alex wrote:
“It holds a monopoly position in surgical robots. As a result, sales and earnings are making a dramatic turn northward. Gross profits are a whopping 63.2% of sales. And recurring revenues are already more than doubling. This is a stock with a great deal of upside potential.”
The call turned out to be a big winner, as Intuitive was one of the five best-performing stocks in the entire market from 2000 to 2020, even beating out the mighty Apple.
Like Intuitive, Alex's new pick is set to revolutionize medicine and could save billions of lives and also dollars in the process.
The Pitch
All the details on this breakthrough stock have been compiled in a special briefing called “The #1 AI Stock: How to Retire on This Obscure Under-$10 Stock.”
It's ours when we sign up to receive The Oxford Communiqué newsletter each month. The cost? $49 for the first year with a 365-day, 100% money-back guarantee.
A slew of bonuses are also included in this offer, such as access to a trio of Oxford model portfolios, “insight emails” from Oxford's network of associates (may be spam), and an HD video series enticingly titled The Millionaire-Maker Private Sessions.
A Better, Faster, Cheaper Way to Discover Drugs
AI is changing the drug discovery process as we speak.
In the past, developing a new drug was extremely time-consuming, expensive, and risky.
A whopping 90% of all drugs fail in trials.
All told, it takes an average of 10 years to bring a drug to market and it costs between $2.5 billion and $12 billion to get there.
Why is it so costly and difficult?
According to MIT, it's a trial and error system.
Scientists spend countless hours testing thousands of molecules hoping that one will show promise.
However, there are so many possible molecules that scientists can only test a tiny fraction of the possible candidates, leaving the majority on the table.
The Dawn of Personalized Medicine
Enter Artificial Intelligence.
In short, AI can now take massive datasets of potential molecules and quickly analyze them to find the ones most perfectly matched to fight a disease.
So instead of searching for a needle in a haystack, AI goes through huge datasets to find the best molecules to provide effective treatments at speeds we could not previously imagine.
The Wall Street Journal reports that this could shrink the time it takes for early-stage drug discovery from years to months.
Typically, when a product or service is ultra-fast, accurate, and costs far less than the competition, it wins the majority of market share.
This is what is about to happen in this case, as one company in particular is set to dominate this new approach to medicine and it isn't just a pipedream.
Its AI has already been used in a real clinical setting to analyze diseases for the best possible available treatment, combing data and producing answers doctors hadn’t previously considered.
Bear in mind, that this is only the early stages of this technology. If history is any indication, it will improve at an exponential rate, getting better and better every year.
Alex believes it will completely revolutionize the entire pharmaceutical industry, let's find out the name of his #1 AI Stock.
Revealing Alexander Green’s “#1 AI Stock”
The clues we get are both ample and specific – the best kind:
- This pharmatech company is working on new treatments for solid tumors, including ovarian and breast cancer tumors.
- It published clinical results in Cancer Discovery that highlight the first AI-supported platform to guide the treatment of patients with advanced blood cancer.
- The company opened a 21,000-square-foot expansion of facilities at The Oxford Science Park, expanding its capacity and efficiency for developing new AI drugs.
- It completed the acquisition of Allcyte, integrating that company’s tissue platform into its drug discovery operations.
Alex made it too easy this time around, his #1 AI Stock is Exscientia plc (Nasdaq: EXAI). It's an exact match like your outfit on the first day of school:
- Exscientia's precision-designed CDK7 inhibitor treats advanced solid tumors, including ovarian and breast cancer tumors.
- In September 2022, a study was published in Blood Cancer Discovery, highlighting its AI-supported precision medicine platform to guide personalized treatment recommendations.
- The company is headquartered in The Oxford Science Park, one of the UK's leading business parks for science and technology companies.
- Back in the summer of 2021, Exscientia acquired personalized AI medicine pioneer Allcyte.
A Future Pharma Giant?
Precision medicine, or personalized medicine as it is sometimes referred to, is a new and better approach to health care, as it is based on each person's unique genetic makeup, rather than the one-size-fits-all approach of the past.
Exscientia's AI-powered precision medicine platform is a step toward this, but it is still in the early stages as I write this.
Revenue is extremely lumpy and comes exclusively from partnership milestone payments, like the kind that was signed with Merck last year and Sanofi before that.
These give Exscientia a cash runway into 2026, which could be a make-or-break year for the company.
Overall, this is more akin to a venture capital bet than an actual investment, especially given that the company recently had to sack its founder and CEO over an “inappropriate relationship with two colleagues.”
Combine this with the fact that I don't have any specialized expertise in the pharma/biotech space and can't tell you whether or not Exscientia's platform is better than the competition, not to mention the lack of revenue/cash flow, and it's an easy pass for me.
Quick Recap & Conclusion
- Alexander Green calls his “#1 AI Stock” the perfect stock because it is undiscovered and trades for just a few dollars a share.
- The company in question has used AI to discover a better, faster, cheaper way to discover drugs and it could “completely revolutionize the entire pharmaceutical industry.”
- All of the details on this breakthrough stock have been compiled in a special briefing “The #1 AI Stock: How to Retire on This Obscure Under-$10 Stock.” It's ours if we sign up to receive The Oxford Communiqué newsletter for $49 for the first year.
- If you read this far, you can skip this step as we were able to reveal Alex's #1 AI Stock for free as Exscientia plc (Nasdaq: EXAI).
- Exscientia's AI-powered precision medicine platform is still in its early stages and isn't generating much revenue at this point, making it more of a venture-style bet than a tangible investment.
Will Exscientia eventually become a pharma giant? Leave a Yes or No in the comments.
Thanks for your detective work and analysis! I love reading all your emails and have invested in some of the companies you cover. I have done a little too much speculating before I heard about Green Bull and have lost more than I would have liked. It’s always nice to get an second, unbiased opinion. Thanks and keep up the good work!